Cargando…

The Relationship between Angiotensin–Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure

BACKGROUND: The valsartan-sacubitril therapy improved the outcomes of patients with acute decompensated heart failure (ADHF) of a reduced ejection fraction (HFrEF). In ADHF patients with preserved ejection fraction (HFpEF), it is not yet clear whether the same treatment regimen may be safely used to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaoliang, Yang, Song, Xu, Zhonglin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484936/ https://www.ncbi.nlm.nih.gov/pubmed/36132549 http://dx.doi.org/10.1155/2022/4298644

Ejemplares similares

Left atrial diameter and atrial fibrillation, but not elevated NT-proBNP, predict the development of pulmonary hypertension in patients with HFpEF
por: LIU, Yi-Xian, et al.
Publicado: (2020)

Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022)

NT-proBNP as a biomarker for hyperdynamic circulation in decompensated cirrhosis
por: Maslennikov, Roman, et al.
Publicado: (2018)

Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023)

Focus on HFpEF in heart failure
por: He, Chunhui, et al.
Publicado: (2022)

Prognostic Impact of Echocardiographic Congestion Grade in HFpEF With and Without Atrial Fibrillation
por: Abe, Haruhiko, et al.
Publicado: (2022)

Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021)

Heart rhythm turbulence and NT-proBNP in decompensated liver cirrhosis – a pilot study
por: Poliwczak, Adam Rafał, et al.
Publicado: (2011)

Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables
por: Curiati, Milena Novaes Cardoso, et al.
Publicado: (2013)

New aspects in cardiorenal syndrome and HFpEF
por: Méndez, Ana Belén, et al.
Publicado: (2022)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
por: Grossekettler, Leonie, et al.
Publicado: (2020)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023)

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
por: Borlaug, Barry A., et al.
Publicado: (2023)

Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD)
por: Claus, Robert, et al.
Publicado: (2020)

miR−21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation
por: Sieweke, Jan-Thorben, et al.
Publicado: (2020)

Left-Side Pressure Index for All-Cause Mortality in Older Adults with HFpEF: Diagnostic Potential for HFpEF and Possible View for HFrEF
por: Hoshida, Shiro
Publicado: (2023)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trial
por: Backhaus, Sören J., et al.
Publicado: (2022)

Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
por: Palazzuoli, A, et al.
Publicado: (2010)

The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
por: Sedlak, Tara L, et al.
Publicado: (2008)

Different determinants of exercise capacity in HFpEF compared to HFrEF
por: Batalli, Arlind, et al.
Publicado: (2017)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants
por: Hiebert, John B., et al.
Publicado: (2016)

Diet-Induced Obesity HFpEF Murine Models
por: Carbone, Salvatore, et al.
Publicado: (2018)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

A preclinical model for phenogroup 3 HFpEF
por: Yousefi, Keyvan, et al.
Publicado: (2019)

Decoding the Pathophysiology of HFpEF With High-Resolution Phenotyping
por: Houstis, Nicholas E.
Publicado: (2020)

Understanding HFpEF With Obesity: Will Pigs Come to the Rescue?
por: Kass, David A.
Publicado: (2021)

Turning Pressure Into Success: Preload Restriction in HFpEF?
por: Atkins, Jessica, et al.
Publicado: (2021)

Renin Feedback Is an Independent Predictor of Outcome in HFpEF
por: Binder, Christina, et al.
Publicado: (2021)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
por: Bonanni, Alice, et al.
Publicado: (2023)

The role of imaging in the selection of patients for HFpEF therapy
por: Baron, Tomasz, et al.
Publicado: (2023)

Use of NT-proBNP in weaning from mechanical ventilation
por: Martini, A, et al.
Publicado: (2011)

NT-proBNP and the diagnosis of exercise-induced myocardial ischaemia
por: De Greef, Jacques, et al.
Publicado: (2008)

Rise and fall of NT-proBNP in aortic valve intervention
por: Hultkvist, Henrik, et al.
Publicado: (2018)

Highly sensitive detection of NT-proBNP by molecular motor
por: Zhang, Jie, et al.
Publicado: (2016)

In-hospital mortality is associated with high NT-proBNP level
por: Benmachiche, Malik, et al.
Publicado: (2018)

Admission NT-ProBNP in Myocardial Infarction: an Alert Sign?
por: da Silva, Luís Beck
Publicado: (2019)

The Potential Role of Salivary NT-proBNP in Heart Failure
por: Rammos, Aidonis, et al.
Publicado: (2023)

BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
por: Lewis, Robert A., et al.
Publicado: (2020)

Are HFpEF and HFmrEF So Different? The Need to Understand Distinct Phenotypes
por: Palazzuoli, Alberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ok05lgs6c0aquv4mn036phq2va